200 related articles for article (PubMed ID: 32443311)
1. Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report.
Sun L; Yang M; Zhang X; Li H; Wu L; Zhang Y; Cai S
Medicine (Baltimore); 2020 May; 99(20):e20053. PubMed ID: 32443311
[TBL] [Abstract][Full Text] [Related]
2. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
Cui Q; Hu Y; Ma D; Liu H
Drug Des Devel Ther; 2021; 15():339-347. PubMed ID: 33536747
[TBL] [Abstract][Full Text] [Related]
3. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
Lan CY; Wang Y; Xiong Y; Li JD; Shen JX; Li YF; Zheng M; Zhang YN; Feng YL; Liu Q; Huang HQ; Huang X
Lancet Oncol; 2018 Sep; 19(9):1239-1246. PubMed ID: 30082170
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review.
Lv Y; Zhang J; Liu F; Song M; Hou Y; Liang N
Medicine (Baltimore); 2019 May; 98(22):e15749. PubMed ID: 31145289
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib is effective in the treatment of advanced pancreatic cancer: a case report.
Li S; Niu M; Deng W; Li N; Wei C; Luo S
Anticancer Drugs; 2022 Jan; 33(1):e558-e561. PubMed ID: 34387586
[TBL] [Abstract][Full Text] [Related]
6. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
7. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
8. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
9. Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report.
Zhang A; Liu B; Xu D; Sun Y
Medicine (Baltimore); 2019 Dec; 98(52):e18435. PubMed ID: 31876723
[TBL] [Abstract][Full Text] [Related]
10. Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.
Sharma R; Graham J; Blagden S; Gabra H
BMC Cancer; 2011 Jul; 11():289. PubMed ID: 21745358
[TBL] [Abstract][Full Text] [Related]
11. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of advanced ovarian cancer with anlotinib: a case report.
Zhang P; Ma L; Wang X; Zhang R; Dong Y
J Int Med Res; 2020 Dec; 48(12):300060520976824. PubMed ID: 33284728
[TBL] [Abstract][Full Text] [Related]
13. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer.
Meyer T; Nelstrop AE; Mahmoudi M; Rustin GJ
Ann Oncol; 2001 Dec; 12(12):1705-9. PubMed ID: 11843248
[TBL] [Abstract][Full Text] [Related]
14. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.
Bozkaya Y; Doğan M; Umut Erdem G; Tulunay G; Uncu H; Arık Z; Demirci U; Yazıcı O; Zengin N
J Obstet Gynaecol; 2017 Jul; 37(5):649-654. PubMed ID: 28325092
[TBL] [Abstract][Full Text] [Related]
16. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy: A case report.
Gao F; Cong X; Liu Z
Medicine (Baltimore); 2020 Oct; 99(40):e22637. PubMed ID: 33019486
[TBL] [Abstract][Full Text] [Related]
18. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
Liu J; Deng YT; Jiang Y
Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer.
Huang S; Sheng G; Lv Q; Li Y; Meng Q; Gao X; Shang Z
J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38670563
[TBL] [Abstract][Full Text] [Related]
20. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
